RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

Doesn't hurt to have one April Fool's jibe on the board :)

Regarding the $10m--The way I read it, there is no serious/competent near term driver, i.e, low probability of HI deal and low probability of definitive SA success; hence the desire for the high upfronts. Mrk data is probably poor also--why would they string along a starving little bio if the study results were positive? Didn't the most recent study rap up a year or so ago?

On another topic:I don't understand why the fear/explanation was; without this deal, Corx was about to go under. These early stage biotech's can trade forever. There will almost always be a route to stay in existence for many of them--if they have something of value. Not that I think it's a good idea (actually it's quite the opposite). ALSE is just one example (however, I don't know what they have of value). Yahoo Finance shows them to have ~$35m in debt (MC is only ~$7m). Is that possible Neuro?